​Par Jean Viallet​
PhD, CEO and Scientific Director at Inovotion
​

INOVOTION (spin-off from Grenoble-Alpes University) is a biotech company with a unique in vivo technology providing efficacy and toxicity evaluations of oncology and immuno-oncology drugs, as well as biomaterial and biocompatibility tests. The assays are both in vivo, and 3Rs-compliant.
​This unique platform provides early analysis for drug candidates from small molecules to biologics, before the classical preclinical stage. By eliminating low-value molecules and biomaterial early, INOVOTION accelerates the drug discovery process, increases R&D productivity, and reduces its costs. 
INOVOTION built this xenograft model using immunocompetent chicken embryos for its powerful intrinsic benefits: fast, robust, affordable, and predictive. These in vivo assays will save time and give clear competitive advantages to researchers. 
​ 
​ This next generation in vivo model covers:
- Efficacy assays for anti-cancer treatments including antibodies and cellular therapies
​ - Early Toxicity assays for drug candidates 
​ - Cancer models development from patient biopsies, CTCs and PDO 
​ - Target Validation in oncology 
​ - Multi-Cancer Screening to (re)position a treatment
​ - Biomaterial and Biocompatibility tests
​ This conference will cover several aspects of tumour growth, metastatic invasion, angiogenesis, immune cell infiltration, toxicity, and biomaterial.
​ 
​ After the conference, Jean Viallet will be available to discuss your research projects. Feel free to also contact him directly at contact@inovotion.com​​

Contactez Odile Filhol-Cochet​